{"name":"AKARI Therapeutics","slug":"akari-therapeutics","ticker":"","exchange":"","domain":"","description":"AKARI Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel treatments for orphan diseases. The company's lead product, Coversin, is in Phase 2 clinical trials, while other programs have been discontinued.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":2815000,"netIncome":-17298000,"cash":47892000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Coversin","genericName":"Coversin","slug":"coversin","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Coversin","genericName":"Coversin","slug":"coversin","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPZlBsVWs1ckU2TmZpX1dIOVVkQ1pzcDJZZTJ6VHc5VDlLYi04MGNFazRGSGNkdy1NSmFQUVVTckFsTzBLSGtfdlROb013QnhtcU44cXpBdy1aUTh6WUQwTEJZbjlqbHozWjZYdUZoUHJPQnh1YW1OV0dydXJpaWgwcXU3Z1ZIYWp5NzEzb3NXcGhEcml5ZHo2Z1F5V1VhV1BNejNiVnhZdUdldUxzLU9raWZLS3Z1dHBTM2ZSVmhjcWlLUkJPNDRsSV9yQmtXR3l1WWxmSU9FZE95R1l3S29nVVRwbjFwRTNuWVdWQVhZam5zWWxsdmlqRUpselhtM01tR3lOaA?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Bullous Pemphigoid Market Forecast 2034: Explore Next-Gen Treatments, Regulatory Milestones, and Competitive Intelligence | DelveInsight - Barchart.com","headline":"Bullous Pemphigoid Market Forecast 2034: Explore Next-Gen Treatments, Regulatory Milestones, and Competitive Intelligenc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNWUZoeXlQSFR1anktZ1lYdTFRb3JpVHQ1YkJfOE9FSkRBeVRHNDYybHJUWVpRbmduVUI5WElIM3ZoNWpqWTQwb3E3QnZVSzRiNzRYRUw2TjF3OFRwc2tTbGcwajZiUlFNVjJnUHBFUUMtOFdIOVUwNmdUckU1NU85Qmg0R2VrazJMaGtOUmFtLS12MHg5VXlhTGxVSEpqREtXMG0xQzJBZVJfRjM3QW9oUm1tUkVyZzgtQlNfSVJNZHhhcVphTnlEWHpXQ1RKbU0?oc=5","date":"2026-04-06","type":"deal","source":"Contract Pharma","summary":"Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload - Contract Pharma","headline":"Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQUUpIV2R5V1ZENDVJS08yMDJZNVNuaUF2TnpVaUt3bUdkLW1VTDlwUDdRbDlxdG0waFk0Yk0zdDIyaHl4RGxTdklkYmotWS1TV0duRnBuTUp0Z2ZkZUJzMnNrMHVYQ0FoaW85M1l6SGZOc2dlX3cwZnExWHNqbk1nM015anVmOFVvR0dUUnZaZWlrVzNkWGtuczJRcVBNRWdadVg5NVRhbUpORlFrTFZ0WjBSM2lNNWtEam9IRDJ0bDJsbXA3SjdOTDQwYw?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Akari Therapeutics (NASDAQ: AKTX) holder reports 8.9% ownership - Stock Titan","headline":"Akari Therapeutics (NASDAQ: AKTX) holder reports 8.9% ownership","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNTF9Zd0x3LWhIU2o2VlYyazFWdkFHT0pFRGo1VDlXUlJ0bkdrdjJFLUhuUEZYNjJyQnRMQ2I2Qkl6M21XdnFyTmVGTWJJVDVBcko1STRYOXZubG5QSDQtb2ZWbVpRVUJkNzM2R04yYnZzZ1ByNzFYalB5UE54cXN6MDdNOXoyVjI1NVBtaHRkbWtDSnZZN0pxWmh3Qkpidmp4ejZ3UDRjVTBCajh0OGJTamhIclMxNTFDS1BZYzZGeEQ4VWFfNVRrdEFtSER4Z3lUc3RaM2EzSDN6eFpwNXpNRXpOa3BIallBUUlldg?oc=5","date":"2026-02-26","type":"pipeline","source":"BioSpace","summary":"Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - BioSpace","headline":"Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNODRkNVkzWFhjRXYyREZieUhIRmd5V3pmOWU1S09OWndmRGZ0dmN6WFduYmMxcUhUNnZHSlUwOXNzRDd4bHpqd0w5aHdMa1h6WmlLRm1GUVYwNnc0MWcyd2xMYWtDVWxyTXJqczlVR0lYdEJZaU0yRWVFRUR1emREM0JCSnBOUWJLVFBIZnQ2ck1sNEliN2Z0enNn?oc=5","date":"2026-01-28","type":"patent","source":"PharmaTimes","summary":"Akari files new patent and advances second ADC targeting CEACAM5 - PharmaTimes","headline":"Akari files new patent and advances second ADC targeting CEACAM5","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPMUJGYjhVYmo2VU9pLUFWSHNSQWg3SWx4aWZ0VFE5ZkhvUmFQQ2E2QUFvTS0xVExKMS1CQnI3U3JpU3AtalZ0LXZIa1VwY2NPR3U1ZUV4WGhpZVA2Rm5MWUxIeko0S29BcW02MU1JcmlHRlp5Wkd6LXFRcmplREJycktQeDZrZkd5aXl3MU5kX3FnMzY4dmsySHVHdUkwUjBVNzBrSWlUOHpUYnJRM3ZXWUF4bkRYLXNfYUE?oc=5","date":"2025-12-29","type":"pipeline","source":"Contract Pharma","summary":"Akari Initiates Manufacturing Activities to Support AKTX-101 Development - Contract Pharma","headline":"Akari Initiates Manufacturing Activities to Support AKTX-101 Development","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-14","type":"pipeline","source":"simplywall.st","summary":"Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - simplywall.st","headline":"Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNQUlMT1RINHNUR1JDUkF6Y0xYWHlLelV5eVZPYWI3ZHF6OXcwTW9zUm1uSE5UNzdCV2lsOFRHTmdKMnJHMmNVY1pSRkpWblpzR29uaUtOS3lOSDUxZk00RHktamVndTB6VlNoVnBpSVVVZVQyRVJ5anRtcnd1dDQxVkxhYU9sYjJ2aERoUlgzWUNDRTVvZjZLbTFNeVJ1R1I4dFNNbGdYdWpEMnlnTl9jbnNDTDNsdw?oc=5","date":"2025-07-24","type":"pipeline","source":"PharmaTimes","summary":"Akari Therapeutics advances research on novel PH1 payload for targeted cancer therapy - PharmaTimes","headline":"Akari Therapeutics advances research on novel PH1 payload for targeted cancer therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOdG5FVEtISmtiaVRZeVNMdElDcm5jVVd0S2xhNUJ3dkpCS2VpQUNMcDVxZjVFWTBDM3Y2b0tBS3BnZ0hVUURraDFrdDA5ZTdaWEN1TU1wNi1SX0ZoOEl4YzE0a2toM0lqWFA1Vy1ZNGp2UFVxQ0dmUUZFdkJqbnRnOFc4NTJHZnVHSEtKM2tZV2gzRTdJaUtKMmhfdEk?oc=5","date":"2025-03-20","type":"pipeline","source":"Yahoo Finance","summary":"Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Yahoo Finance","headline":"Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNUExNdTBRQWRlUGxKbTFHeHVMc1VQY1c5Z1dnSVRYRDZ3X0xWVE9RNG0tUHlsaXJ1ZDJOTXVSVG94cDYtb1EweURDUzNhRXFFTzdlSFVySktMU0lzU3d4RmxXelpleWNKWWNsRDJnVkNlMU1feTFJUDMwZnlXbjR4Uzh0X0xwUUd3MFY4bmhvanYxM3cxcUhTTw?oc=5","date":"2025-03-20","type":"pipeline","source":"citybiz","summary":"Akari Therapeutics Appoints Abizer Gaslightwala as CEO - citybiz","headline":"Akari Therapeutics Appoints Abizer Gaslightwala as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9JVmxTODNCZERiRkJKTW0tclBhZW9BRmJJc3FLa2dlNHFQcU9zZ2wwYlpjYi1KLXprUHVWanIxQUJrMlFqVHdiMThpc0JIUlpSNUlyVks4N0o1cG4xUHZHc0dyNmJRWUkyMktseHl6elhOeEVOdnM1OG1qUDdQNlE?oc=5","date":"2024-05-17","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye - Fierce Biotech","headline":"Chutes & Ladders—Atai appoints co-CEO and a Fierce goodbye","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9FcEVOZjE1S0lNckFVRl9LWjNrSWFFSTRmYXBTdnpuQ0dyS3hoVmZFZFZGV2FkTG9MVlV2WUluNkh0eWRyY3l3SjRTTEhxVVZvTW5tMTYycmFTaTU1U09NbWN6OEpuLVE1eUZ1aTZiMFB1TDltVE45NA?oc=5","date":"2024-03-06","type":"deal","source":"Pharmaceutical Technology","summary":"Akari Therapeutics enters merger deal with Peak Bio - Pharmaceutical Technology","headline":"Akari Therapeutics enters merger deal with Peak Bio","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2815000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17298000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":0,"cashHistory":[],"totalAssets":47892000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}